Alexander C. Sacher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexander C. Sacher has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Andrew Kung
Department of Internal Medicine, New York Presbyterian Queens, Flushing, New York, USA; Department of Cardiology, New York Presbyterian Queens, Flushing, New York, USA; Department of Internal Medicine, Stony Brook Southampton Hospital, Southampton, New York, USA
2 shared publicationsJasneel Kahlam
Department of Internal Medicine, New York Presbyterian Queens, Flushing, New York, USA; Department of Cardiology, New York Presbyterian Queens, Flushing, New York, USA; Department of Internal Medicine, Stony Brook Southampton Hospital, Southampton, New York, USA
2 shared publicationsRafsan Ahmed
Department of Internal Medicine, New York Presbyterian Queens, Flushing, New York, USA; Department of Cardiology, New York Presbyterian Queens, Flushing, New York, USA; Department of Internal Medicine, Stony Brook Southampton Hospital, Southampton, New York, USA
2 shared publications- Aasim Akthar Ahmed
Department of Internal Medicine, St. Francis Medical Center, Monroe, LA 71201, USA
1 shared publication - Andrew Kung
Division of Internal Medicine, New York Presbyterian Queens, Flushing, NY 11355, USA
1 shared publication - David Song
Icahn School of Medicine at Mount Sinai - Elmhurst Hospital Center, Elmhurst, NY, USA
1 shared publication
Latest Publications
- Open Access
- 9 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (31) , 105333
Early Recognition of Giant Cell Myocarditis in a Patient With Fascicular Ventricular Tachycardia
- 9 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (31) , 105333
Open AccessEarly Recognition of Giant Cell Myocarditis in a Patient With Fascicular Ventricular Tachycardia
- Open Access
- 26 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3720
Efficacy and Safety of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia: Meta-Analysis of Randomized Controlled Trials
Background: Patients with arrhythmias, particularly paroxysmal supraventricular tachycardia (PSVT), face an increased risk of cardiac complications. Currently, non-parenteral medications for rapid PSVT cessation are lacking. Etripamil, a novel intranasal, short-acting calcium channel blocker, offers a rapid onset and the potential for unsupervised PSVT management. However, data on its use in arrhythmia management remain limited. Aims: We aimed to assess the efficacy and safety of 70 mg of etripamil compared with placebo in the treatment of PSVT. Methods: We systematically searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) from inception to April 2025. We calculated pooled risk ratios (RRs) with 95% confidence intervals (CIs) using random or common effects models, depending on the heterogeneity. Results: Four RCTs including 540 patients were analyzed. Etripamil demonstrated higher conversion rates to the sinus rhythm at 15 min (RR 1.84 [95% CI: 1.32–2.48]), 30 min (RR 1.80 [95% CI: 1.38–2.35]), and 60 min (RR 1.24 [95% CI: 1.04–1.48]). PSVT recurrence rates were similar between groups (RR 0.52 [95% CI: 0.20–1.34]). Adverse events (AEs) and severe AEs were comparable between etripamil and the placebo. Etripamil was associated with higher rates of nasal discomfort, nasal congestion, rhinorrhea, and epistaxis but not with increased bradyarrhythmia, atrial fibrillation, or non-sustained ventricular tachycardia. Conclusions: Etripamil appears to be a promising treatment for cardiac arrhythmias. Larger long-term RCTs are needed to confirm its safety and efficacy in clinical practice.
- 26 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3720
Open AccessEfficacy and Safety of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia: Meta-Analysis of Randomized Controlled Trials
Background: Patients with arrhythmias, particularly paroxysmal supraventricular tachycardia (PSVT), face an increased risk of cardiac complications. Currently, non-parenteral medications for rapid PSVT cessation are lacking. Etripamil, a novel intranasal, short-acting calcium channel blocker, offers a rapid onset and the potential for unsupervised PSVT management. However, data on its use in arrhythmia management remain limited. Aims: We aimed to assess the efficacy and safety of 70 mg of etripamil compared with placebo in the treatment of PSVT. Methods: We systematically searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) from inception to April 2025. We calculated pooled risk ratios (RRs) with 95% confidence intervals (CIs) using random or common effects models, depending on the heterogeneity. Results: Four RCTs including 540 patients were analyzed. Etripamil demonstrated higher conversion rates to the sinus rhythm at 15 min (RR 1.84 [95% CI: 1.32–2.48]), 30 min (RR 1.80 [95% CI: 1.38–2.35]), and 60 min (RR 1.24 [95% CI: 1.04–1.48]). PSVT recurrence rates were similar between groups (RR 0.52 [95% CI: 0.20–1.34]). Adverse events (AEs) and severe AEs were comparable between etripamil and the placebo. Etripamil was associated with higher rates of nasal discomfort, nasal congestion, rhinorrhea, and epistaxis but not with increased bradyarrhythmia, atrial fibrillation, or non-sustained ventricular tachycardia. Conclusions: Etripamil appears to be a promising treatment for cardiac arrhythmias. Larger long-term RCTs are needed to confirm its safety and efficacy in clinical practice.
- Open Access
- 17 March 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (8) , 102667
Myocarditis
- 17 March 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (8) , 102667
Open AccessMyocarditis